|Bid||55.76 x 13500|
|Ask||56.17 x 54600|
|Day's Range||54.81 - 56.29|
|52 Week Range||42.74 - 61.13|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||26.56|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
With Novo Nordisk at the top of the list, these are the 10 biggest biotechnology companies by 12-month trailing revenue.
During same 10-year period, Eisai and Abbott were worst performers in measure Continue reading...
Bagsværd, Denmark, 20 July 2020 – On 11 May 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European.